Gilead Sciences’ (GILD) new HIV prevention shot, lenacapavir, hit it out of the park in a late-stage trial, showing 100% effectiveness. 2,000 women participated in the trial, and none of…
Stocks
-
-
Editor’s Note: This article was originally published on November 21, 2022. This article has absolutely nothing to do with trend following or the markets. I have two friends; one whose…
-
In this edition of StockCharts TV‘s The Final Bar, Dave recaps a day where technology shares struggles, with leading names like NVDA and MU dropping bearish engulfing patterns to indicate short-term distributions.…
-
In this edition of StockCharts TV‘s The Final Bar, Dave answers viewer questions on using technical indicators on leveraged and inverse ETFs like SOXL and SOXS, buying breakouts below the 200-day moving…
-
Who would have thought a mid-week break would halt the stock market’s winning streak? Maybe the hot PMI reading leaked, or traders and investors felt the stock market was getting…
-
Moving averages are a crucial charting tool, but many of us aren’t getting the most out of them. In this edition of StockCharts TV‘s StockCharts in Focus, Grayson shows you how to…
-
In this StockCharts TV video, Mary Ellen reviews the broader markets, takes a close look at NVDA and other year-to-date winners that sold off last week, and shares top candidates in…
-
Last week, the broader market Indices hit another new high on Thursday before pulling back into Friday’s close. Not all areas participated, however, as the recently explosive move into AI…
-
The Dow Jones Industrial Average ($INDU) may not be the comprehensive measure of the US economy it once was in the early 20th century. However, if you’re holding (or looking…
-
Note to the reader: This is the twenty-fifth and final in .